NCCN Guidelines for Treatment of Localized Prostate Cancer

Kelvin A. Moses, MD, PhD, FACS, Associate Professor of Urology and Director of Comprehensive Cancer Clinic at Vanderbilt University Medical Center in Nashville, Tennesses and Chair of the National Comprehensive Cancer Network (NCCN) Guidelines Panel for Prostate Cancer Early Detection, discusses updated NCCN Guidelines for treatment of localized prostate cancer. He reviews initial risk-stratification and staging workup for clinically localized disease, including clinical/pathological features, additional evaluation, and initial therapy across various risk groups. Dr. Moses notes that all treatment modalities have specific risks, nomograms can help employ risk-adapted treatment strategies, and optimal patient selection paired with shared decision-making leads to the best patient outcomes.

[vincentmahon]

Does NCCN provide guidance or an evaluation on the use of focal therapies - e.g. Tulsa, IRE / Nanoknife, HIFU, Cryotherapy, Proton Beam and others?